News
DHR
226.25
-0.39%
-0.88
Danaher (DHR) Valuation Check After Analyst Upgrade and 2026 Earnings Recovery Narrative
Simply Wall St · 2d ago
Morgan Stanley Ups the Ante on These 2 Life Science Tool Stocks
TipRanks · 2d ago
USCL, BKNG, BSX, DHR: Large Outflows Detected at ETF
NASDAQ · 3d ago
My 3 Big Market Predictions For 2026: The Shift I'm Positioning For Now
Seeking Alpha · 3d ago
The Bull Case For Danaher (DHR) Could Change Following New Fiduciary-Duty Probe Into Its Boardroom
Simply Wall St · 3d ago
Danaher Price Target Announced at $270.00/Share by Morgan Stanley
Dow Jones · 4d ago
Danaher Initiated at Overweight by Morgan Stanley
Dow Jones · 4d ago
Morgan Stanley Initiates Coverage On Danaher with Overweight Rating, Announces Price Target of $270
Benzinga · 4d ago
Tracking Akre Capital Management Portfolio - Q3 2025 Update
Seeking Alpha · 4d ago
Danaher initiated with an Overweight at Morgan Stanley, named Top Pick in group
TipRanks · 5d ago
Weekly Report: what happened at DHR last week (1124-1128)?
Weekly Report · 5d ago
HALPER SADEH LLC ENCOURAGES DANAHER CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
PR Newswire · 11/28 23:34
Martin Zweig Detailed Fundamental Analysis - DHR
NASDAQ · 11/28 17:00
Danaher Stock Sale: Executive Chairman’s Multi-Million Dollar Move
TipRanks · 11/27 02:08
Danaher (DHR): Exploring Valuation After Q3 Earnings Beat and Bioprocessing Growth
Simply Wall St · 11/27 01:21
DuPont Can Become a 'Compounder.' Why the Stock Could Gain 20%.
Barron‘s · 11/26 21:58
Revvity (RVTY) Up 9.5% Since Last Earnings Report: Can It Continue?
NASDAQ · 11/26 16:30
Danaher Stock: Is DHR Underperforming the Healthcare Sector?
Barchart · 11/26 06:48
Is Danaher Corp Gaining or Losing Market Support?
Benzinga · 11/24 20:00
Notable ETF Inflow Detected - XLV, PFE, DHR, MDT
NASDAQ · 11/24 15:50
More
Webull provides a variety of real-time DHR stock news. You can receive the latest news about Danaher Corporation through multiple platforms. This information may help you make smarter investment decisions.
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.